Privia Health price target raised to $21 from $19 at Barclays

Barclays analyst Andrew Mok raised the firm’s price target on Privia Health (PRVA) to $21 from $19 and keeps an Equal Weight rating on the shares post the Q3 report. Privia showed steady progress with modest outperformance in multiple books of business enabling a free cash flow raise, the analyst tells investors in a research note.